Changchun Jinsai Pharmaceutical Co., Ltd. obtained the first production approval of biological preparation in 2014

Human growth hormone is mainly used in the treatment of dwarfism Research shows that about 2 / 3 of dwarfism is caused by heredity and puberty retardation, and 1 / 3 of pathological dwarfism is caused by growth hormone deficiency, precocious puberty, chromosomal abnormality, intrauterine growth retardation and Turner syndrome According to the results of the fifth national census of the National Bureau of statistics of China, there are more than 4.3 million children suffering from dwarfism in China, of which about 1.44 million are pathological The main function of human growth hormone is to promote the growth and development of human body and maintain the normal physiological function of tissues and organs Recombinant human growth hormone can regulate metabolism, stimulate protein synthesis, accelerate fat metabolism and promote the growth and development of bone and muscle tissue At the same time, because it can promote wound healing, it is also used in the surgical treatment or operation of injury and severe burn As a kind of protein drug, recombinant human growth hormone has the disadvantages of short half-life, easy degradation by protease, easy removal by kidney and so on Due to the short half-life in the body, in order to achieve the curative effect, it needs to be injected every day, and the course of treatment takes a long time, which brings great pain to the children PEGylation is a good solution to overcome the above shortcomings The molecular weight of modified recombinant human growth hormone increases correspondingly When it passes through the kidney, it can't be filtered by the glomerulus in time, thus prolonging the retention time in the blood Changchun Jinsai Pharmaceutical Co., Ltd is the leading enterprise of recombinant human growth hormone products in China According to the market share pattern of minenet - recombinant human growth hormone in 2012, the company ranks first with more than 57% share Recombinant human growth hormone products are the company's key products The sales volume in 2012 accounted for more than 83% of the company's total performance, and the sales situation in the past five years also showed a steady upward trend Figure 1: Sales of recombinant human growth hormone of Changchun kinsay Pharmaceutical Co., Ltd in recent five years according to the relevant regulations of the State Food and drug administration, the long-term growth hormone product needs to pass GMP certification after receiving the official approval certificate issued by the State Food and drug administration, so the specific production and market promotion time of the product cannot be determined temporarily As the first approved production enterprise, it is worth further attention whether Changchun Jinsai pharmaceutical industry can seize this new starting point, achieve rapid growth and drive its parent company, Changchun hi tech, to continue to be the number one high price stock in the two cities At present, Changchun Jinsai Pharmaceutical Co., Ltd is the first enterprise in China to obtain the approval for the production of polyethylene glycol recombinant human growth hormone injection, while the products declared by its competitors, Anke biology and Xiamen Tebao, a subsidiary of Tonghua Dongbao Co., Ltd., are still in the clinical trial stage In recent years, the sales volume of recombinant human growth hormone products in China has maintained a steady growth year by year It is estimated that the market scale of recombinant human growth hormone in China will reach about 2.23 billion yuan by 2015 The recombinant human growth hormone after PEGylation can prolong the action time of the drug and improve the therapeutic effect accordingly The market potential in the future can not be ignored